CN1860121A - 用于预防和治疗癌症的取代咪唑并嘧啶 - Google Patents

用于预防和治疗癌症的取代咪唑并嘧啶 Download PDF

Info

Publication number
CN1860121A
CN1860121A CNA2004800279669A CN200480027966A CN1860121A CN 1860121 A CN1860121 A CN 1860121A CN A2004800279669 A CNA2004800279669 A CN A2004800279669A CN 200480027966 A CN200480027966 A CN 200480027966A CN 1860121 A CN1860121 A CN 1860121A
Authority
CN
China
Prior art keywords
pyrimidine
imidazo
methylthiophenyl
nmr
methoxyphenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2004800279669A
Other languages
English (en)
Chinese (zh)
Inventor
J·L·卡特娜鲁伊斯
C·费雷伦斯加列米
A·费尔南德斯塞拉特
C·塞拉科马斯
D·巴尔萨罗佩斯
C·拉古纳斯阿纳尔
C·萨尔切多罗卡
A·费尔南德斯加西亚
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratorios Salvat SA
Original Assignee
Laboratorios Salvat SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratorios Salvat SA filed Critical Laboratorios Salvat SA
Publication of CN1860121A publication Critical patent/CN1860121A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CNA2004800279669A 2003-07-30 2004-07-29 用于预防和治疗癌症的取代咪唑并嘧啶 Pending CN1860121A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200301906 2003-07-30
ES200301906 2003-07-30

Publications (1)

Publication Number Publication Date
CN1860121A true CN1860121A (zh) 2006-11-08

Family

ID=34130555

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2004800279669A Pending CN1860121A (zh) 2003-07-30 2004-07-29 用于预防和治疗癌症的取代咪唑并嘧啶

Country Status (14)

Country Link
US (1) US20060189631A1 (https=)
EP (1) EP1660500B1 (https=)
JP (1) JP2007500160A (https=)
KR (1) KR20060034303A (https=)
CN (1) CN1860121A (https=)
AT (1) ATE380816T1 (https=)
AU (1) AU2004263297A1 (https=)
BR (1) BRPI0412636A (https=)
CA (1) CA2534292A1 (https=)
DE (1) DE602004010680T2 (https=)
EA (1) EA009038B1 (https=)
ES (1) ES2298798T3 (https=)
WO (1) WO2005014598A1 (https=)
ZA (1) ZA200601706B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012159565A1 (zh) * 2011-05-23 2012-11-29 南京英派药业有限公司 6-(芳基甲酰)咪唑并[1，2-a]嘧啶和6-(芳基甲酰)[1，2，4]三唑并[4，3-a]嘧啶作为Hedgehog通路抑制剂及其应用

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007096764A2 (en) * 2006-02-27 2007-08-30 Glenmark Pharmaceuticals S.A. Bicyclic heteroaryl derivatives as cannabinoid receptor modulators
US7683060B2 (en) 2006-08-07 2010-03-23 Incyte Corporation Triazolotriazines as kinase inhibitors
ME02372B (me) 2006-11-22 2016-06-20 Incyte Holdings Corp Imidazotriazini i imidazopiramidini kao inhibitori kinaze
EP2062893A1 (en) * 2007-10-18 2009-05-27 Bayer Schering Pharma AG Fused imidazoles for cancer treatment
UY31292A1 (es) * 2007-08-14 2009-03-31 Imidazoles biciclicos fusionados
WO2009143211A2 (en) 2008-05-21 2009-11-26 Incyte Corporation Salts of 2-fluoro-n-methyl-4-[7-(quinolin-6-yl-methyl)- imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same
MX2012004341A (es) 2009-10-16 2012-10-05 Rib X Pharmaceuticals Inc Compuestos antimicrobianos y metodos para fabricar y utilizar los mismos.
EA025304B1 (ru) 2010-02-03 2016-12-30 Инсайт Холдингс Корпорейшн ИМИДАЗО[1,2-b][1,2,4]ТРИАЗИНЫ В КАЧЕСТВЕ c-Met ИНГИБИТОРОВ
US8410117B2 (en) * 2010-03-26 2013-04-02 Hoffmann-La Roche Inc. Imidazopyrimidine derivatives
SI2694510T1 (sl) 2011-04-07 2016-02-29 Bayer Intellectual Property Gmbh Imidazopiridazini kot inhibitorji AKT kinaze
UY35400A (es) * 2013-03-15 2014-10-31 Novartis Ag Compuestos y composiciones para el tratamiento de enfermedades parasitarias
US9296754B2 (en) 2013-03-15 2016-03-29 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
US9233961B2 (en) 2013-03-15 2016-01-12 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
US9186361B2 (en) 2013-03-15 2015-11-17 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
TWI674263B (zh) 2013-12-19 2019-10-11 瑞士商諾華公司 用於治療寄生蟲疾病之化合物及組合物
HK1249758A1 (zh) 2015-03-11 2018-11-09 Melinta Therapeutics, Inc. 抗微生物化合物及其制备和使用方法
US11098047B2 (en) 2016-05-06 2021-08-24 BioVersys AG Antimicrobials and methods of making and using same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3455924A (en) * 1967-02-08 1969-07-15 Upjohn Co Dianisylimidazoles
US5700826A (en) * 1995-06-07 1997-12-23 Ontogen Corporation 1,2,4,5-tetra substituted imidazoles as modulators of multi-drug resistance
ES2140354B1 (es) * 1998-08-03 2000-11-01 S A L V A T Lab Sa Imidazo (1,2a) azinas sustituidas como inhibidores selectivos de la cox-2.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012159565A1 (zh) * 2011-05-23 2012-11-29 南京英派药业有限公司 6-(芳基甲酰)咪唑并[1，2-a]嘧啶和6-(芳基甲酰)[1，2，4]三唑并[4，3-a]嘧啶作为Hedgehog通路抑制剂及其应用

Also Published As

Publication number Publication date
EA009038B1 (ru) 2007-10-26
DE602004010680T2 (de) 2009-01-02
ZA200601706B (en) 2007-09-26
ATE380816T1 (de) 2007-12-15
BRPI0412636A (pt) 2006-09-26
EP1660500A1 (en) 2006-05-31
JP2007500160A (ja) 2007-01-11
WO2005014598A1 (en) 2005-02-17
EA200600330A1 (ru) 2006-08-25
KR20060034303A (ko) 2006-04-21
AU2004263297A1 (en) 2005-02-17
DE602004010680D1 (de) 2008-01-24
US20060189631A1 (en) 2006-08-24
ES2298798T3 (es) 2008-05-16
EP1660500B1 (en) 2007-12-12
CA2534292A1 (en) 2005-02-17

Similar Documents

Publication Publication Date Title
CN1860121A (zh) 用于预防和治疗癌症的取代咪唑并嘧啶
CN109574871B (zh) 一种乙酰氨基偶氮苯类衍生物及其制备与应用
CN1278263A (zh) 2,3－二芳基－吡唑并[1,5－b]哒嗪衍生物,其制备方法和用作环氧酶2(cox－2)抑制剂的用途
CN105980388B (zh) 化合物
KR102774784B1 (ko) Jak를 억제하기 위한 화합물 및 방법
PE20051089A1 (es) Derivados de pirazolo [1,5-a] pirimidin-7-il-amina como inhibidores de quinasa de proteina
CN1186492A (zh) 咪唑并[1,2－α]吡啶衍生物
CN1771234A (zh) 吡咯并三嗪激酶抑制剂的制备方法
CN1458933A (zh) 噻吩并嘧啶化合物及其盐以及其制备方法
CN1500091A (zh) 4,6-二氨基嘧啶并[5,4-d]嘧啶的制备方法
CN1842529A (zh) 用作蛋白激酶抑制剂的化合物和组合物
CN1321157A (zh) 作为选择性COX－2抑制剂的取代的咪唑并[1,2a]吖嗪
EP2616467A1 (en) Substituted azaindoles
CN100344615C (zh) 制备N－(吡咯并[2,3－d]嘧啶－5－基)酰基谷氨酸衍生物的方法及中间体
CN1533378A (zh) 制备喹唑啉的方法
CN1319096A (zh) 喹唑啉衍生物及其药物用途
CN1413215A (zh) 吡唑并哒嗪衍生物的制备方法
CN1830964A (zh) 4－取代苯氨基－3－硝基喹啉类化合物及其制备方法和用途
CN1255387C (zh) 可用作选择性cox－2抑制剂的嘧啶衍生物
CN1890245A (zh) 用于制备微管蛋白抑制剂的方法
CN1914213A (zh) 噻唑并嘧啶的制备方法
CN1228330C (zh) 咪唑衍生物或它们的盐
CN1122033C (zh) 三唑并嘌呤衍生物、含有该衍生物的药物组合物
MXPA06001262A (en) Substituted imidazopyrimidines for the prevention and treatment of cancer
EP4301722A1 (en) Photoredox radical benzylation process

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
AD01 Patent right deemed abandoned
C20 Patent right or utility model deemed to be abandoned or is abandoned